MoonLake Immunotherapeutics (MLTX)
| Market Cap | 609.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -176.16M |
| Shares Out | 63.50M |
| EPS (ttm) | -2.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,222,680 |
| Open | 9.00 |
| Previous Close | 9.16 |
| Day's Range | 8.90 - 9.64 |
| 52-Week Range | 5.95 - 62.75 |
| Beta | 1.10 |
| Analysts | Buy |
| Price Target | 37.63 (+291.98%) |
| Earnings Date | Nov 6, 2025 |
About MLTX
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for MLTX stock is "Buy." The 12-month stock price target is $37.63, which is an increase of 291.98% from the latest price.
News
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman
SAN FRANCISCO , Oct. 14, 2025 /PRNewswire/ -- Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) saw the price of their shares crater $55.75, or about 90%, after the company announced disastrous ...
MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations o...
MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options If you purchased or acquir...
MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results -- Contact BFA Law
NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations ...
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
LOS ANGELES , Oct. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MoonLake Immunotherap...
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
LOS ANGELES , Oct. 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX...
MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's Investigation
BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations. Investors who have lost money in their Mo...
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics Investigated for Securities Fraud after 90% Stock Drop – Contact BFA Law
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations ...
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost Money
NEW YORK, Oct. 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations ...
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
LOS ANGELES--(BUSINESS WIRE)--MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX.
MLTX BREAKING NEWS: BFA Law is Investigating MoonLake Immunotherapeutics (NASDAQ: MLTX) for Securities Fraud after Stock Drops 90% on Drug Trial Results, Investors Urged to Contact the Firm
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations ...
MoonLake Immunotherapeutics - Special Call
MoonLake Immunotherapeutics - Special Call Company Participants Matthias Bodenstedt - Chief Financial Officer Jorge da Silva - Co-Founder, CEO & Director Kristian Reich Conference Call Participants Al...
MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts
MoonLake Immunotherapeutics‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials.
BREAKING: MoonLake Immunotherapeutics Shares Down Over 85%; Investors Should Contact Block & Leviton to Potentially Recover Losses
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations.
Moonlake: What's Happening With MLTX Stock?
MoonLake Immunotherapeutics (NASDAQ: MLTX), a biopharmaceutical firm in the clinical stage, experienced substantial fluctuations last week. The stock climbed 10% on Friday, September 26, as investors ...
MoonLake shares crash 88% after mixed trial results raise doubts over skin drug
Shares of Swiss biotech MoonLake Immunotherapeutics tumbled 88% to $7.45 in premarket trading on Monday after the company reported mixed outcomes from two late-stage trials of its experimental skin dr...
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program ...
2 Logical Mid-Cap Biotech Buyout Targets
There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on t...
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflamma...
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest
MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is...
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.